Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Blackrock Inc (BLK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Blackrock Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $299.01 (market cap $39.89B), while Blackrock Inc trades at $1,034.01 (market cap $160.59B). The key difference: Blackrock Inc is far larger — about 4× Alnylam Pharmaceuticals, Inc.'s market cap, and Blackrock Inc pays a 2.21% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | BLK | |
|---|---|---|
Market Cap | $39.89B | $160.59B |
Sector | Health | Financials |
52-Week High | $491.22 | $1.20K |
52-Week Low | $278.09 | $922.90 |
Enterprise Value | $38.15B | $162.41B |
Volume | — | 641,547 |
Dividend Yield | — | 2.21% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
BlackRock (BLK) trades at $1,036.11, up 1.61% with strong earnings momentum after beating estimates for three consecutive quarters. The stock shows bearish technical signals but maintains solid fundamentals with $24.22B revenue and 24.4% net margin. Recent developments include the launch of a new Nasdaq-100 ETF challenging Invesco QQQ, with Q2 2026 earnings expected on July 15.
Outlook remains positive with 76% analyst buy ratings and $1,270 consensus price target representing 22.6% upside. Key risks include market volatility affecting asset management fees and competitive pressure in ETF space. The company's pivot to private markets and AI-driven growth initiatives provide long-term opportunities.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Blackrock Inc
BlackRock, Inc. provides investment management services to institutional clients and to retail investors through various investment vehicles. The Company manages funds, as well as offers risk management services. BlackRock serves governments, companies, and foundations worldwide.
Read more on BLK →
